Gerald made the following comments today in an ema
Post# of 30066
Posted On: 08/21/2014 7:03:15 PM
Gerald made the following comments today in an email regarding an error he made in a recent communication with a shareholder.
While we've been fortunate up to this point to have a CEO who cares about keeping shareholders informed using email and social media, expect that to change as the company prepares to list on NASDAQ. No quiet period speculation... it's just the right time for the company to take their communications with shareholders to the next level. I'm thankful we had a direct line to our CEO for the last several years, but clearly the time has come for that to change. I believe there are exciting times ahead for shareholders as this story continues to unfold.
I suggest all future inquiries be made via our Investor Relations Director. Gerald should be free to focus on the company strategy and negotiations, not having to deal with individual shareholder issues and concerns directly.
Aimee Boutcher
Director of Investor Relations
Amarantus BioScience Holdings, Inc.
408-737-2734 x101
ir@amarantus.com
http://ir.stockpr.com/amarantus/ir-contacts
Quote:
In going forward I will be doing less emailing and personal communication, as there is no formal QC process for it.
The Company is getting to the point where institutions will become involved and this will create problems. A small, but important typo leads to confusion and we can ill afford it.
While we've been fortunate up to this point to have a CEO who cares about keeping shareholders informed using email and social media, expect that to change as the company prepares to list on NASDAQ. No quiet period speculation... it's just the right time for the company to take their communications with shareholders to the next level. I'm thankful we had a direct line to our CEO for the last several years, but clearly the time has come for that to change. I believe there are exciting times ahead for shareholders as this story continues to unfold.
I suggest all future inquiries be made via our Investor Relations Director. Gerald should be free to focus on the company strategy and negotiations, not having to deal with individual shareholder issues and concerns directly.
Aimee Boutcher
Director of Investor Relations
Amarantus BioScience Holdings, Inc.
408-737-2734 x101
ir@amarantus.com
http://ir.stockpr.com/amarantus/ir-contacts
(0)
(0)